Ritu Baral, an analyst from TD Cowen, maintained the Buy rating on Vera Therapeutics. The associated price target is $60.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Ritu Baral has given her Buy rating due to a combination of factors related to Vera Therapeutics’ promising clinical trial results and regulatory progress. The company’s Phase 3 ORIGIN-3 study of atacicept in IgA nephropathy (IgAN) showed significant efficacy, with a 67% placebo-adjusted reduction in Gd-IgA1 and an 81% resolution in hematuria. These results were consistent across various patient subgroups, indicating a robust therapeutic effect of atacicept.
Furthermore, the safety profile of atacicept was encouraging, with no cases of hypogammaglobulinemia or opportunistic infections reported. The rate of serious adverse events was notably lower in the atacicept group compared to the placebo group. Vera Therapeutics is on track for a Biologics License Application (BLA) submission in the fourth quarter of 2025, with a projected accelerated approval in the United States by 2026. These factors collectively support the Buy rating as they highlight the potential for atacicept to become a significant treatment option for IgAN.
In another report released yesterday, LifeSci Capital also maintained a Buy rating on the stock with a $70.00 price target.